Market News & Trends
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. recently announced positive in vivo data for PNV-5032, as a potential treatment for….
Charles River Laboratories Licenses Genedata Biologics
Genedata recently announced Charles River Laboratories International, Inc., has chosen Genedata Biologics to support their rapidly expanding global biopharma operations across multiple groups in the…
TriRx Completes Acquisition of Elanco Manufacturing Facility in Speke, UK
TriRx Pharmaceutical Services, LLC, a leading international CDMO, recently announced it has finalized and closed on its agreement with Elanco Animal Health Incorporated to acquire the ownership and operations of….
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease
Regio Biosciences recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol….
SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive & Untreatable Tumors
SEngine Precision Medicine Inc. and Oncodesign recently announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and…..
Cognizant Announces Partnership With Medable to Deliver Strategy, Deployment & Support Services for Decentralized Clinical Trials
Cognizant recently announced a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable’s software-as-a-service platform for decentralized clinical trials. Cognizant will…
Bormioli Pharma Keeps on Innovating on Glass to Achieve a Better Performing & More Sustainable Product
As the celebrations for the International Year of Glass are currently underway in Geneva, Switzerland, Bormioli Pharma recently announced new research and innovation projects. Through…
Gattefossé Strengthens its CSR Approach & Reaches Two Major Milestones
In line with its CSR commitment, Gattefossé has received ISO 14001:2015 certification for its main production site in France and has been ranked in the…
Biomerica Announces Positive Topline Results From the Endpoint Clinical Trial
Biomerica, Inc. recently announced positive topline results from the endpoint clinical trial of its InFoods IBS diagnostic-guided therapy (DGT), with the trial showing statistically significant…
Xanadu Bio Obtains Licenses & Options to Novel Platform Technologies From Yale University to Develop Intranasal SARS CoV-2 mRNA Vaccine Booster
Xanadu Bio recently announced a broad exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed….
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial
Ocuphire Pharma, Inc. recently announced it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically….
Ovid Therapeutics & Healx to Enter Strategic Partnership
Ovid Therapeutics and Healx recently announced Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol. Under the agreement, Healx plans to….
Eyenovia Concludes Type A Meeting With FDA Related to MydCombi NDA Resubmission
Eyenovia, Inc. recently announced that the company successfully completed a Type A meeting with the US FDA related to the refiling of the NDA for…
Recce Pharmaceuticals Announces Positive Safety Data From Third Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd recently reported Phase 1 intravenous (IV) clinical trial of RECCE 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg…
Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 & MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells
Kintara Therapeutics, Inc. recently announced the US PTO has issued to Kintara United States Patent No. 11,234,955 covering a method of treating brain tumors including…
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation recently announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of….
POP Biotechnologies Vaccine Technology to Enter Phase 3 Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies recently announced the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean…
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
Evelo Biosciences, Inc. recently announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate…
Theralase Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
Theralase Technologies Inc. has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (COVID-19) vaccine…..